(VIANEWS) – Freeport (FCX), Albany International Corporation (AIN), Simulations Plus (SLP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Freeport (FCX)
25.4% sales growth and 14.38% return on equity
Freeport-McMoRan Inc. engages in the mining of mineral properties in North America, South America, and Indonesia. It primarily explores for copper, gold, molybdenum, silver, and other metals. The company's assets include the Grasberg minerals district in Indonesia; Morenci, Bagdad, Safford, Sierrita, and Miami in Arizona; Chino and Tyrone in New Mexico; and Henderson and Climax in Colorado, North America, as well as Cerro Verde in Peru and El Abra in Chile. The company was formerly known as Freeport-McMoRan Copper & Gold Inc. and changed its name to Freeport-McMoRan Inc. in July 2014. Freeport-McMoRan Inc. was incorporated in 1987 and is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, Freeport has a trailing twelve months EPS of $1.28.
PE Ratio
Freeport has a trailing twelve months price to earnings ratio of 38.65. Meaning, the purchaser of the share is investing $38.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.38%.
Moving Average
Freeport’s value is below its 50-day moving average of $50.23 and way above its 200-day moving average of $41.38.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.3%, now sitting on 23.79B for the twelve trailing months.
2. Albany International Corporation (AIN)
13.3% sales growth and 11.96% return on equity
Albany International Corp. engages in the textile and materials processing businesses. The company operates in two segments, Machine Clothing (MC) and Albany Engineered Composites (AEC). The MC segment designs, manufactures, and markets paper machine clothing for use in manufacturing papers, paperboards, tissues, and towels. This segment offers forming, pressing, and drying fabrics, as well as process belts. It also provides customized and consumable fabrics that are used in the manufacturing process in the pulp, corrugator, nonwovens, fiber cement, building products, tannery, and textile industries. This segment sells its products directly to end-user customers. The AEC segment designs, develops, and manufactures composite structures primarily to customers in the commercial and defense aerospace industries. The company operates in the United States, Switzerland, France, Brazil, China, Mexico, and internationally. Albany International Corp. was founded in 1895 and is headquartered in Rochester, New Hampshire.
Earnings Per Share
As for profitability, Albany International Corporation has a trailing twelve months EPS of $3.56.
PE Ratio
Albany International Corporation has a trailing twelve months price to earnings ratio of 24.8. Meaning, the purchaser of the share is investing $24.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.96%.
Sales Growth
Albany International Corporation’s sales growth is 21.9% for the present quarter and 13.3% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 7, 2024, the estimated forward annual dividend rate is 1.04 and the estimated forward annual dividend yield is 1.18%.
3. Simulations Plus (SLP)
10.7% sales growth and 6.16% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.52.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 97.98. Meaning, the purchaser of the share is investing $97.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Volume
Today’s last reported volume for Simulations Plus is 52220 which is 50% below its average volume of 104455.
4. W.W. Grainger (GWW)
6.7% sales growth and 57.74% return on equity
W.W. Grainger, Inc., together with its subsidiaries, distributes maintenance, repair, and operating products and services primarily in North America, Japan, the United Kingdom, and internationally. The company operates through two segments, High-Touch Solutions N.A. and Endless Assortment. The company provides safety, security, material handling and storage equipment, pumps and plumbing equipment, cleaning and maintenance, and metalworking and hand tools. It also offers technical support and inventory management services. The company serves smaller businesses to large corporations, government entities, and other institutions, as well as commercial, healthcare, and manufacturing industries through sales and service representatives, and electronic and ecommerce channels. W.W. Grainger, Inc. was founded in 1927 and is headquartered in Lake Forest, Illinois.
Earnings Per Share
As for profitability, W.W. Grainger has a trailing twelve months EPS of $36.24.
PE Ratio
W.W. Grainger has a trailing twelve months price to earnings ratio of 26.63. Meaning, the purchaser of the share is investing $26.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 57.74%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 4% and 10.8%, respectively.
Sales Growth
W.W. Grainger’s sales growth is 3.8% for the present quarter and 6.7% for the next.
Volume
Today’s last reported volume for W.W. Grainger is 211203 which is 9.62% below its average volume of 233703.
5. ICON plc (ICLR)
6.5% sales growth and 7.55% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $8.24.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 39.26. Meaning, the purchaser of the share is investing $39.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.
